CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 European Hematology Association Congress
Oncology Conference Multimedia
View more videos >>
Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML
Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL
Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML
Oncology Conference Articles
Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL
At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL
The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.
Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML
Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with
-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.
Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL
The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.
CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL
A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
Compound CAR T-Cell Therapy Shows Promise for AML
A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.
PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma
PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.
Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option
The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.
Overcoming Challenges in the Management of mCRC
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
FDA Grants Avelumab/Axitinib Combo Priority Review for RCC
Hereditary Prostate Cancer—What Urologists Should Know
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.